Company’s Global Manufacturing Facility Move Forward in Almere, The Netherlands
New York – October 30, 2014 – AXIM Biotechnologies, Inc. (OTC: AXIM) is proud to announce that it has secured the down payment on land to build the Company’s manufacturing facility. The land is 6,000 square meters located at the industrial estate Stichtsekant in the city of Almere, The Netherlands. AXIM Biotech’s future high-tech, state-of-the-art factory will be located on the corner of Fort de Gagel and Fort Blauwkape.
With the first payment secured, in the next month AXIM Biotech will work with the builder and architects on drafting building plans and a detailed engineering building plan with respect to permit applications and subsequent approvals. After the final purchase of the land, AXIM Biotech will break ground on construction.
“We are extremely grateful to the government of the province of Flevoland for allowing AXIM Biotech to establish manufacturing in Almere,” states Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “The factory plans are compliant with the highest European and International standards and will produce unique pharmaceutical and nutraceutical products – all from agricultural hemp.”
AXIM Biotechnologies is planning the state-of-the-art Almere facility to feature: a clean laboratory zone, storage areas, office and technical rooms as well as manufacturing facility furnishings. AXIM’s global manufacturing hub in Almere will have the capacity to process raw materials and manufacture the Company’s innovative hemp-based pharmaceutical, nutraceutical and consumer products, which are all based on their own intellectual property. Project design and feasibility has begun and the Company is targeting the completion of construction by 2017.
“This is an exciting time for life sciences as AXIM establishes a fully ‘green’ agricultural hemp-based biotech manufacturing facility,” states Lekhram Changoer, MSc., BSc., and Chief Technical Officer. “At AXIM, the hemp manufacturing byproducts will be used and result in a net negative carbon footprint that is beneficial to the environment.”
Holding exclusive rights to the world’s first patented cannabinoid release chewing gum and, with it, plans to conduct clinical trials for pain and spasticity associated with Multiple Sclerosis (MS) set in the EU, AXIM Biotech is leading the life sciences industry with hemp-based innovations. AXIM is focused upon unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. THC, CBD, CBG, CBN, etc.) and finding solutions for conditions for which there is currently no effective treatment including: MS, spasticity, pain, Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease.
Research shows that the industrial hemp plant can produce more than 25,000 products. Focusing on innovations in health and the environment, AXIM Biotech’s Almere facility will include manufacturing in the following product categories:
- Functional foods
- Clean energy
AXIM® Biotech has been featured by media outlets including: Yahoo! Finance, Marketwatch, ABC, NBC, CBS, Telemundo, WGN, Univision, Marijuana Investor News, FOX Business, MainStreet.com, MJ Freeway, Chemical & Engineering News, Dental Tribune, Pharmaceutical Commerce, Dental Products Report and MJI News. For more information, visit AXIM Biotech’s website.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 858-264-6601.
About AXIM Biotechnologies:
AXIM Biotechnologies (OTC: AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227